Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients with Tumor Induced Osteomalacia


About this study

This study aims to identify cases of FGF23-mediated oncogenic osteoomalacia in which the underlying phosphaturic mesenchymal has not been found and perform 68Ga-DOTATATE PET in these patients to localize the tumor.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults (18 years of age or older).
  • Seen at Mayo Clinic, Rochester for FGF23 mediated osteomalacia.
  • Willing/able to provide informed consent to participate in the study.

Exclusion Criteria: 

  • Pregnancy.
  • Prisoners.
  • Subjects diagnosed with heritable hypophosphatemic rickets/osteomalacia.
  • Subjects who do not consent for the study or withdraw consent during the duration of the study.
  • Subjects in whom tumor localization and successful resection has already occurred.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Drake, M.D., Ph.D.

Closed for enrollment

Contact information:

Amber Stephan C.Ph.T.

More information


Publications are currently not available

Mayo Clinic Footer